Miriam Blasi
Overview
Explore the profile of Miriam Blasi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zerdes I, Kamali C, Johannsdottir B, Blasi M, Assmann C, Kazdal D, et al.
Lung Cancer
. 2024 Dec;
199:108065.
PMID: 39705826
Introduction: Several prognostic scores were developed for non-small-cell lung cancer (NSCLC) patients with brain metastases (BM), though limited data reported for the KRAS-mutated subgroup. KRAS-targeted therapies have improved extracranial and...
2.
Budczies J, Romanovsky E, Kirchner M, Neumann O, Blasi M, Schnorbach J, et al.
Br J Cancer
. 2024 Jun;
131(3):524-533.
PMID: 38866964
Background: Predictive biomarkers in use for immunotherapy in advanced non-small cell lung cancer are of limited sensitivity and specificity. We analysed the potential of activating KRAS and pathogenic TP53 mutations...
3.
Blasi M, Kuon J, Luders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, et al.
Eur J Cancer
. 2024 May;
205:114130.
PMID: 38789333
No abstract available.
4.
Kemper M, Soltani Germy P, Acker F, Luan J, Griesinger F, Tufman A, et al.
Oncol Res Treat
. 2024 Apr;
47(6):312-315.
PMID: 38574467
No abstract available.
5.
Acker F, Luan J, Soltani Germy P, Kemper M, Blasi M, Griesinger F, et al.
Oncol Res Treat
. 2024 Mar;
47(6):306-311.
PMID: 38527447
No abstract available.
6.
Blasi M, Kuon J, Luders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, et al.
Eur J Cancer
. 2024 Jan;
199:113556.
PMID: 38271745
Background: The efficacy of checkpoint inhibitors for non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METΔ14ex) remains controversial. Materials And Methods: 110 consecutive METΔ14ex NSCLC patients receiving first-line...
7.
Blasi M, Kuon J, Shah R, Bozorgmehr F, Eichhorn F, Liersch S, et al.
Clin Lung Cancer
. 2023 Jun;
24(7):e282-e290.
PMID: 37391339
Objective: First-line pembrolizumab alone, as approved for PD-L1 ≥50%, or with chemotherapy was analyzed in older non-small-cell lung cancer (NSCLC) patients, for whom evidence is scarce. Materials And Methods: A...
8.
Christopoulos P, Schlenk R, Kazdal D, Blasi M, Lennerz J, Shah R, et al.
Genes Chromosomes Cancer
. 2023 Feb;
62(9):557-563.
PMID: 36852573
Leveraging real-world data (RWD) for drug access is necessary to overcome a key challenge of modern precision oncology: tackling numerous low-prevalence oncogenic mutations across cancers. Withholding a potentially active medication...
9.
Blasi M, Eichhorn M, Christopoulos P, Winter H, Heussel C, Herth F, et al.
BMC Pulm Med
. 2022 Jun;
22(1):255.
PMID: 35761214
Background: Data are currently insufficient to support the use of adjuvant chemotherapy (ACT) after surgical resection for stage II or III non-small cell lung cancer (NSCLC) in patients aged ≥ ...
10.
Kuon J, Blasi M, Unsold L, Vogt J, Mehnert A, Alt-Epping B, et al.
Support Care Cancer
. 2021 Dec;
30(4):3131-3140.
PMID: 34877613
Purpose: The purpose of this study is to investigate changes over time in quality of life (QoL) in incurable lung cancer patients and the impact of determinants like molecular alterations...